MedTrace Logo

Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy

NCT00549692 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2012-09-27

No results posted yet for this study

Summary

The purpose of this study is to compare omega-3 fatty acids with placebo for efficacy in retardation of increase of serum creatinine(SCr) in IgA Nephropathy

Conditions

Interventions

DRUG

Omega-3 fatty acid ethylester90

Dosage form :1g soft capsule Dosage : two capsules, twice a day.

Sponsors & Collaborators

  • Pronova BioPharma ASA

    collaborator INDUSTRY

  • Kuhnil Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Suhnggwon Kim, Professor · Seoul National University Hospital

  • Byung-Joo Park, MD,PhD,FISPE · Seoul National University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2012-08-31
Completion
2012-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00549692 on ClinicalTrials.gov